Structure of Asciminib

Asciminib (Asciminib) is a kinase inhibitor. The chemical name of this API is N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-3-yl)pyridine-3-carboxamide-hydrogen chloride (1/1). Aceminid film-coated tablets are available for oral use in two strengths containing 20 mg and 40 mg Aceminid hydrochloride (equivalent to 21.62 mg and 43.24 mg Aceminid hydrochloride, respectively).

Aximini is an allosteric inhibitor ofBCR-ABL1 tyrosine kinase. It binds to the myristoyl pocket of the ABL1 part of the fusion protein and locks it in an inactive conformation, thereby preventing its oncogenic activity. In most patients with chronic myelogenous leukemia (CML), disease progression is primarily driven by a translocation of the Philadelphia chromosome that creates the oncogenic fusion gene BCR-ABL1 between the BCR and ABL1 genes. This fusion gene produces a synthetic fusion protein, BCR-abl 1, which exhibits elevated tyrosine kinase and transforming activity that promotes chronic myelogenous leukemia proliferation.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminib currently sold overseas is very expensive. Generic drugs of Asiminil are also produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rate effects), and the price is relatively cheap. For more drug information and specific prices, please consult Yaode’s medical consultant.